Anti-NY-ESO-1 immune response and survival benefit after LV305 therapy in patients with advanced sarcoma and other solid tumors
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2017)
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2017)